ADMA Biologics Inc (NASDAQ:ADMA) Shares Purchased by New York State Teachers Retirement System

New York State Teachers Retirement System lifted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 96.2% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 221,890 shares of the biotechnology company's stock after acquiring an additional 108,800 shares during the quarter. New York State Teachers Retirement System owned 0.09% of ADMA Biologics worth $4,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in ADMA Biologics during the 4th quarter valued at $19,076,000. JPMorgan Chase & Co. grew its position in ADMA Biologics by 272.5% during the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares during the last quarter. Victory Capital Management Inc. grew its position in ADMA Biologics by 52.8% during the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares during the last quarter. Sei Investments Co. grew its position in ADMA Biologics by 147.2% during the 4th quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of ADMA Biologics by 6.6% during the 4th quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after acquiring an additional 28,500 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve Elms sold 194,749 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,621 shares of company stock worth $9,644,269. Insiders own 3.70% of the company's stock.

Analyst Ratings Changes

ADMA has been the topic of a number of research reports. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial raised their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

ADMA Biologics Stock Performance

NASDAQ ADMA traded down $0.40 on Monday, reaching $17.88. 1,830,293 shares of the stock were exchanged, compared to its average volume of 3,160,966. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The firm has a market capitalization of $4.27 billion, a PE ratio of 21.04 and a beta of 0.43. The company's 50-day simple moving average is $20.24 and its two-hundred day simple moving average is $18.73. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company's quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. Analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.